GoodRx Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- 84.3
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $200.40M | $0.02 | $0.08 |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | After market close | $194.00M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | After market close | $194.80M | $0.02 | $0.09 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | After market close | $196.00M | $0.00 | $0.08 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | $203.10M | $0.04 | $0.09 |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | After market close | $203.00M | $0.03 | $0.09 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | $198.60M | $0.02 | $0.09 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $195.30M | $0.01 | $0.08 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 10, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | full-year 2026 | $240.00M to $250.00M | Raised |
| Revenue | full-year 2026 | $790.00M to $805.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements GoodRx filed with the SEC
GOODRX REPORTS SECOND QUARTER 2026 RESULTS
Results of operations · EX-99.1 to Form 8-K
GOODRX REPORTS FIRST QUARTER 2026 RESULTS
Results of operations · EX-99.1 to Form 8-K
GOODRX REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS
Results of operations · EX-99.1 to Form 8-K
GOODRX REPORTS THIRD QUARTER 2025 RESULTS
Results of operations · EX-99.1 to Form 8-K
GOODRX REPORTS SECOND QUARTER 2025 RESULTS
Results of operations · EX-99.1 to Form 8-K
GOODRX REPORTS FIRST QUARTER 2025 RESULTS
Results of operations · EX-99.1 to Form 8-K
GOODRX REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS
Results of operations · EX-99.1 to Form 8-K
GOODRX REPORTS THIRD QUARTER 2024 RESULTS
Results of operations · EX-99.1 to Form 8-K
Ronald E. Bruehlman Joins GoodRx Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
GOODRX REPORTS SECOND QUARTER 2024 RESULTS
Results of operations · EX-99.1 to Form 8-K
Ian T. Clark Joins GoodRx Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Simon Patterson Joins GoodRx Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
GOODRX REPORTS FIRST QUARTER 2024 RESULTS
Results of operations · EX-99.1 to Form 8-K
GoodRx Interim CEO Extends Commitment to Company
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
GOODRX REPORTS FOURTH QUARTER AND FULL YEAR 2023 RESULTS
Results of operations · EX-99.1 to Form 8-K
GoodRx Announces Preliminary Fourth Quarter and Full Year 2023 Results and Early Expectations for First Quarter and Full Year 2024
Results of operations · EX-99.1 to Form 8-K
GoodRx Appoints Kelly J. Kennedy to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
GOODRX REPORTS THIRD QUARTER 2023 RESULTS
Results of operations · EX-99.1 to Form 8-K
GOODRX REPORTS SECOND QUARTER 2023 RESULTS
Results of operations · EX-99.1 to Form 8-K
GOODRX REPORTS FIRST QUARTER 2023 RESULTS
Results of operations · EX-99 to Form 8-K
GoodRx Expands Executive Team With New Interim CEO
Results of operations · Executive or director change · EX-99.1 to Form 8-K
GOODRX REPORTS FOURTH QUARTER AND FULL YEAR 2022 RESULTS
Results of operations · EX-99 to Form 8-K
GOODRX REPORTS THIRD QUARTER 2022 RESULTS
Results of operations · EX-99.1 to Form 8-K
GoodRx Releases Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Q2 2022 Letter to Shareholders August 8, 2022
Results of operations · EX-99.2 to Form 8-K
GoodRx Releases First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Q1 2022 Letter to Shareholders May 9, 2022
Results of operations · EX-99.2 to Form 8-K
GoodRx Agrees to Acquire vitaCare, A Tech-Enabled Pharmacy Services Platform
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
GoodRx Releases Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
GoodRx helps Americans get the healthcare they need at a price they can afford. GoodRx helps my patients pay less
Results of operations · EX-99.2 to Form 8-K
GoodRx Releases Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Q3 2021 Letter to Shareholders November 10, 2021
Results of operations · EX-99.2 to Form 8-K